The prognostic significance of p53, p63 and her2 expression in non-muscle-invasive bladder cancer in relation to treatment with bacille Calmette–Guerin

摘要

Objective To investigate whether the immunohistochemical expression of p53, p63 and her2eu is correlated with the prognosis of tumour recurrence and progression in patients with non-muscle invasive (NMI) bladder cancer. Patients and methods In all, 88 patients diagnosed with NMI transitional cell carcinoma of the bladder in a Urology Department from May 2009 to April 2014 were included in the study. Paraffin-embedded specimens were obtained by transurethral resection of the bladder tumours. Sections on haematoxylin and eosin-stained slides were examined histologically and tumour grade was classified according to the World Health Organisation system (2004) Mostofi classification. The sections were evaluated using p63, p53 and her2eu immunohistochemical staining before and after immunotherapy with bacille Calmette–Guerin (BCG), and patients were followed up for 36 months in the Urology Department. Results For tumour grade there was a significant relationship with the overexpression of p53 ( P = 0.010), her2 ( P = 0.025) and negativity of p63 ( P = 0.025). There was no significant relationship between p53 or her2eu overexpression and tumour stage. However, there was a significant correlation ( P = 0.005) between p63 negativity and tumour stage. There was a significant relationship between p53 ( P = 0.01), her2eu ( P = 0.025) overexpression and p63 negativity ( P = 0.005) and tumour recurrence and progression. Conclusion Patients with transitional cell carcinoma who are selected for BCG treatment should preferably be positively immunoreactive for p63, but negative for both p53 and her2eu. These patients were less susceptible to recurrence and/or progression after BCG adjuvant therapy. Further studies are needed to investigate the relationship between these three markers and treatment with anti-her2eu therapies.